SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally... Show more
The RSI Indicator for SIBN moved out of oversold territory on June 23, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In of the 25 cases the stock moved higher. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on June 27, 2025. You may want to consider a long position or call options on SIBN as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SIBN just turned positive on June 30, 2025. Looking at past instances where SIBN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
SIBN moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SIBN advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
SIBN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SIBN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SIBN entered a downward trend on June 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SIBN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.828) is normal, around the industry mean (24.307). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (4.369) is also within normal values, averaging (42.612).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SIBN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
a sacroiliac joint medical device company
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
DFRSX | 19.14 | 0.14 | +0.74% |
DFA Asia Pacific Small Company I | |||
FGFRX | 43.10 | N/A | N/A |
Federated Hermes Intl Leaders R | |||
NMVLX | 12.31 | N/A | N/A |
Nuance Mid Cap Value Institutional | |||
TRZKX | 74.00 | N/A | N/A |
T. Rowe Price International Discovery Z | |||
MSDMX | 14.13 | N/A | N/A |
Morgan Stanley Emerging Mkt ex China R6 |
A.I.dvisor indicates that over the last year, SIBN has been loosely correlated with AORT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SIBN jumps, then AORT could also see price increases.
Ticker / NAME | Correlation To SIBN | 1D Price Change % | ||
---|---|---|---|---|
SIBN | 100% | +0.66% | ||
AORT - SIBN | 46% Loosely correlated | +0.33% | ||
TMCI - SIBN | 43% Loosely correlated | +1.16% | ||
UFPT - SIBN | 43% Loosely correlated | -2.74% | ||
ATRC - SIBN | 42% Loosely correlated | -2.52% | ||
KIDS - SIBN | 42% Loosely correlated | +1.28% | ||
More |